Celgene cancer drug acquisition may bode well for life science M&A
Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of covalent drugs, which latch onto or bond with target cells and effectively neutralize those cells. Avila’s lead therapeutic, AVL-292, is a lymphoma and autoimmune drug in phase […]